adenine has been researched along with Lymphoma, Non-Hodgkin in 47 studies
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.19 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. ( Amorim, S; Balasubramanian, S; Bandyopadhyay, N; de Vries, R; Flinn, I; Fourneau, N; Friedberg, JW; Hellemans, P; Hivert, B; Morschhauser, F; Oki, Y; Smit, JW; Thieblemont, C; Vermeulen, J; Westin, J; Younes, A, 2014) |
| " Common nonhematologic adverse events were fatigue (56%), nausea (53%), anorexia (41%), and diarrhea (41%) and were mostly low grade." | 3.11 | Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. ( Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA, 2022) |
| " The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%])." | 2.90 | Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. ( Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019) |
| " In vitro exposure of leukemia cells to CAde showed that it was eight times less toxic as compared to CdA." | 2.71 | Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. ( Albertioni, F; Juliusson, G; Larsson, R; Liliemark, J; Lindemalm, S, 2004) |
| "To determine if variability in toxicity of amonafide during phase II trials could be correlated with pharmacokinetic variability." | 2.68 | Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. ( Allen, SL; Costanza, M; Henderson, IC; Ratain, MJ; Rosner, G; Schilsky, RL; Van Echo, DA, 1995) |
| "Waldenström's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients." | 2.61 | Updates in prognostication and treatment of Waldenström's macroglobulinemia. ( Advani, P; Ailawadhi, S; Paulus, A, 2019) |
| " Ibrutinib is an orally bioavailable and highly specific BTK inhibitor that was recently approved for treatment of patients with recurrent CLL and mantle cell lymphoma (MCL)." | 2.52 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ( Lynn Wang, Y; Smith, SM; Zhang, SQ; Zhang, SY, 2015) |
| "As oral targeted agents, such as ibrutinib, become more widely used, understanding the impact of suboptimal dosing on overall survival (OS) and progression-free survival (PFS) outside of clinical trials is imperative." | 1.51 | Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. ( Baloga, E; Baran, AM; Barr, PM; Casulo, C; Friedberg, JW; Helber, M; Moore, J; Reagan, P; Williams, AM; Zent, CS, 2019) |
| "We describe the use of a mutant T-lymphosarcoma cell line, AraC-6-1, which has an abnormally high dCTP pool and a low TTP pool, to test this prediction." | 1.26 | Mechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells. ( Caras, IW; Coffino, P; MacInnes, MA; Martin, DW; Persing, DH, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (14.89) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 5 (10.64) | 29.6817 |
| 2010's | 29 (61.70) | 24.3611 |
| 2020's | 5 (10.64) | 2.80 |
| Authors | Studies |
|---|---|
| Stephens, DM | 1 |
| Huang, Y | 1 |
| Ruppert, AS | 1 |
| Walker, JS | 1 |
| Canfield, D | 1 |
| Cempre, CB | 1 |
| Fu, Q | 1 |
| Baker, S | 1 |
| Hu, B | 1 |
| Shah, H | 1 |
| Vadeboncoeur, R | 1 |
| Rogers, KA | 1 |
| Bhat, S | 1 |
| Jaglowski, SM | 1 |
| Lockman, H | 1 |
| Lapalombella, R | 1 |
| Byrd, JC | 2 |
| Woyach, JA | 1 |
| Ruchlemer, R | 1 |
| Ben-Ami, R | 1 |
| Bar-Meir, M | 1 |
| Brown, JR | 1 |
| Malphettes, M | 1 |
| Mous, R | 1 |
| Tonino, SH | 1 |
| Soussain, C | 1 |
| Barzic, N | 1 |
| Messina, JA | 1 |
| Jain, P | 1 |
| Cohen, R | 1 |
| Hill, B | 1 |
| Mulligan, SP | 1 |
| Nijland, M | 1 |
| Herishanu, Y | 1 |
| Benjamini, O | 1 |
| Tadmor, T | 1 |
| Okamoto, K | 1 |
| Arthurs, B | 1 |
| Gottesman, B | 1 |
| Kater, AP | 1 |
| Talha, M | 1 |
| Eichhorst, B | 1 |
| Korem, M | 1 |
| Bogot, N | 1 |
| De Boer, F | 1 |
| Rowe, JM | 1 |
| Lachish, T | 1 |
| Malek, AE | 1 |
| Nieto, Y | 1 |
| Szvalb, AD | 1 |
| Siddiqui, S | 1 |
| Shafi, MA | 1 |
| Hwang, JP | 1 |
| Raad, II | 1 |
| Torres, HA | 1 |
| Jiménez, I | 1 |
| Carabia, J | 1 |
| Bobillo, S | 1 |
| Palacio, C | 1 |
| Abrisqueta, P | 1 |
| Pagès, C | 1 |
| Nieto, JC | 1 |
| Castellví, J | 1 |
| Martínez-Ricarte, F | 1 |
| Escoda, L | 1 |
| Perla, C | 1 |
| Céspedes Torrez, DH | 1 |
| Boix, J | 1 |
| Purroy, N | 1 |
| Puigdefàbregas, L | 1 |
| Seoane, J | 1 |
| Bosch, F | 2 |
| Crespo, M | 1 |
| Law, SC | 1 |
| Hoang, T | 1 |
| O'Rourke, K | 1 |
| Tobin, JWD | 1 |
| Gunawardana, J | 1 |
| Loo-Oey, D | 1 |
| Bednarska, K | 1 |
| Merida de Long, L | 1 |
| Sabdia, MB | 1 |
| Hapgood, G | 1 |
| Blyth, E | 1 |
| Clancy, L | 1 |
| Hennig, S | 1 |
| Keane, C | 1 |
| Gandhi, MK | 1 |
| Krebs, S | 1 |
| Mauguen, A | 1 |
| Yildirim, O | 1 |
| Hatzoglou, V | 1 |
| Francis, JH | 1 |
| Schaff, LR | 1 |
| Mellinghoff, IK | 1 |
| Schöder, H | 1 |
| Grommes, C | 1 |
| Moyo, TK | 1 |
| Wilson, CS | 1 |
| Moore, DJ | 1 |
| Eischen, CM | 1 |
| Murthy, V | 1 |
| Weaving, S | 1 |
| Paneesha, S | 1 |
| Bernasconi, E | 1 |
| Gaudio, E | 1 |
| Lejeune, P | 1 |
| Tarantelli, C | 1 |
| Cascione, L | 1 |
| Kwee, I | 1 |
| Spriano, F | 1 |
| Rinaldi, A | 1 |
| Mensah, AA | 1 |
| Chung, E | 1 |
| Stathis, A | 1 |
| Siegel, S | 1 |
| Schmees, N | 1 |
| Ocker, M | 1 |
| Zucca, E | 1 |
| Haendler, B | 1 |
| Bertoni, F | 1 |
| Schaffer, M | 2 |
| Chaturvedi, S | 1 |
| Davis, C | 1 |
| Aquino, R | 1 |
| Stepanchick, E | 1 |
| Versele, M | 1 |
| Liu, Y | 1 |
| Yang, J | 1 |
| Lu, R | 1 |
| Balasubramanian, S | 3 |
| Battistello, E | 1 |
| Katanayeva, N | 1 |
| Dheilly, E | 1 |
| Tavernari, D | 1 |
| Donaldson, MC | 1 |
| Bonsignore, L | 1 |
| Thome, M | 1 |
| Christie, AL | 1 |
| Murakami, MA | 1 |
| Michielin, O | 1 |
| Ciriello, G | 1 |
| Zoete, V | 1 |
| Oricchio, E | 1 |
| Rhodes, J | 1 |
| Mato, A | 1 |
| Sharman, JP | 1 |
| Rodgers, TD | 1 |
| Reagan, PM | 1 |
| Illerhaus, G | 1 |
| Schorb, E | 1 |
| Kasenda, B | 1 |
| Jurczak, W | 2 |
| Długosz-Danecka, M | 1 |
| Rivas Navarro, F | 1 |
| Williams, AM | 1 |
| Baran, AM | 1 |
| Casulo, C | 1 |
| Reagan, P | 1 |
| Friedberg, JW | 2 |
| Helber, M | 1 |
| Moore, J | 1 |
| Baloga, E | 1 |
| Zent, CS | 1 |
| Barr, PM | 1 |
| Dolgin, E | 1 |
| Younes, A | 2 |
| Brody, J | 1 |
| Carpio, C | 1 |
| Lopez-Guillermo, A | 1 |
| Ben-Yehuda, D | 1 |
| Ferhanoglu, B | 1 |
| Nagler, A | 1 |
| Ozcan, M | 1 |
| Avivi, I | 1 |
| Caballero Barrigón, MD | 1 |
| Hellmann, A | 1 |
| Kuss, B | 1 |
| Ma, DDF | 1 |
| Demirkan, F | 1 |
| Yağci, M | 1 |
| Horowitz, NA | 1 |
| Marlton, P | 1 |
| Cordoba, R | 1 |
| Wrobel, T | 1 |
| Buglio, D | 1 |
| Streit, M | 1 |
| Hodkinson, BP | 1 |
| Alvarez, J | 1 |
| Ceulemans, R | 1 |
| de Jong, J | 1 |
| Wang, SS | 1 |
| Fourneau, N | 2 |
| Nastoupil, LJ | 1 |
| Lunning, MA | 1 |
| Vose, JM | 1 |
| Schreeder, MT | 1 |
| Siddiqi, T | 1 |
| Flowers, CR | 1 |
| Cohen, JB | 1 |
| Burger, JA | 1 |
| Wierda, WG | 1 |
| O'Brien, S | 1 |
| Sportelli, P | 1 |
| Miskin, HP | 1 |
| Purdom, MA | 1 |
| Weiss, MS | 1 |
| Fowler, NH | 1 |
| Advani, P | 1 |
| Paulus, A | 1 |
| Ailawadhi, S | 1 |
| Bhatt, V | 1 |
| Alejandro, L | 1 |
| Michael, A | 1 |
| Ganetsky, A | 1 |
| Wang, M | 1 |
| Xu, W | 1 |
| Li, JY | 1 |
| Viganò, M | 1 |
| Mangia, G | 1 |
| Lampertico, P | 1 |
| Koskinas, JS | 1 |
| Deutsch, M | 1 |
| Adamidi, S | 1 |
| Skondra, M | 1 |
| Tampaki, M | 1 |
| Alexopoulou, A | 1 |
| Manolakopoulos, S | 1 |
| Pectasides, D | 1 |
| Zinzani, PL | 1 |
| Thieblemont, C | 1 |
| Morschhauser, F | 1 |
| Flinn, I | 1 |
| Amorim, S | 1 |
| Hivert, B | 1 |
| Westin, J | 1 |
| Vermeulen, J | 1 |
| Bandyopadhyay, N | 1 |
| de Vries, R | 1 |
| Hellemans, P | 1 |
| Smit, JW | 1 |
| Oki, Y | 1 |
| Maddocks, K | 1 |
| Christian, B | 1 |
| Jaglowski, S | 1 |
| Flynn, J | 1 |
| Jones, JA | 1 |
| Porcu, P | 1 |
| Wei, L | 1 |
| Jenkins, C | 1 |
| Lozanski, G | 1 |
| Blum, KA | 1 |
| Zhang, SQ | 1 |
| Smith, SM | 1 |
| Zhang, SY | 1 |
| Lynn Wang, Y | 1 |
| Yang, H | 1 |
| Wang, Y | 1 |
| Zhan, J | 1 |
| Xia, Y | 1 |
| Sun, P | 1 |
| Bi, XW | 1 |
| Liu, PP | 1 |
| Li, ZM | 1 |
| Li, S | 1 |
| Zou, BY | 1 |
| Jiang, WQ | 1 |
| Wang, T | 1 |
| Lu, Y | 1 |
| Polk, A | 1 |
| Chowdhury, P | 1 |
| Murga-Zamalloa, C | 1 |
| Fujiwara, H | 1 |
| Suemori, K | 1 |
| Beyersdorf, N | 1 |
| Hristov, AC | 1 |
| Lim, MS | 1 |
| Bailey, NG | 1 |
| Wilcox, RA | 1 |
| Alfaro, J | 1 |
| Pérez de Arce, F | 1 |
| Belmar, S | 1 |
| Fuentealba, G | 1 |
| Avila, P | 1 |
| Ureta, G | 1 |
| Flores, C | 1 |
| Acuña, C | 1 |
| Delgado, L | 1 |
| Gaete, D | 1 |
| Pujala, B | 1 |
| Barde, A | 1 |
| Nayak, AK | 1 |
| Upendra, TVR | 1 |
| Patel, D | 1 |
| Chauhan, S | 1 |
| Sharma, VK | 1 |
| Kanno, S | 1 |
| Almirez, RG | 1 |
| Hung, DT | 1 |
| Chakravarty, S | 1 |
| Rai, R | 1 |
| Bernales, S | 1 |
| Quinn, KP | 1 |
| Pham, SM | 1 |
| McCullagh, E | 1 |
| Votruba, I | 1 |
| Otová, B | 1 |
| Holý, A | 1 |
| Rago, A | 1 |
| Lichtner, M | 1 |
| Mecarocci, S | 1 |
| Marocco, R | 1 |
| Cenfra, N | 1 |
| Belvisi, V | 1 |
| Del Borgo, C | 1 |
| Cimino, G | 1 |
| Mastroianni, CM | 1 |
| Winer, ES | 1 |
| Ingham, RR | 1 |
| Castillo, JJ | 1 |
| Leonard, JP | 1 |
| SARTORELLI, AC | 1 |
| UPCHURCH, HF | 1 |
| COSTAKEL, O | 1 |
| CERECEDO, LR | 1 |
| SMITH, MJ | 1 |
| VICENTE, J | 1 |
| FURTH, JJ | 1 |
| HO, P | 1 |
| Lindemalm, S | 1 |
| Liliemark, J | 1 |
| Juliusson, G | 1 |
| Larsson, R | 1 |
| Albertioni, F | 1 |
| Enomoto, M | 1 |
| Nishiguchi, S | 1 |
| Seki, S | 1 |
| Yamane, T | 1 |
| Hino, M | 1 |
| Castelló Miralles, I | 1 |
| Del Val Antoñana, A | 1 |
| Muñoz Vicente, M | 1 |
| Moreno-Osset, E | 1 |
| Caras, IW | 1 |
| MacInnes, MA | 1 |
| Persing, DH | 1 |
| Coffino, P | 1 |
| Martin, DW | 2 |
| Ratain, MJ | 1 |
| Rosner, G | 1 |
| Allen, SL | 1 |
| Costanza, M | 1 |
| Van Echo, DA | 1 |
| Henderson, IC | 1 |
| Schilsky, RL | 1 |
| de Kreuk, AM | 1 |
| Jonkhoff, AR | 1 |
| Zevenbergen, A | 1 |
| Hendriks, EC | 1 |
| Schuurhuis, GJ | 1 |
| Ossenkoppele, GJ | 1 |
| Dräger, AM | 1 |
| van Oostveen, JW | 1 |
| Huijgens, PC | 1 |
| Gudas, LJ | 1 |
| Cohen, A | 1 |
| Ullman, B | 1 |
| Marshak, A | 1 |
| Marshak, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma[NCT02303392] | Phase 1 | 34 participants (Actual) | Interventional | 2015-03-11 | Active, not recruiting | ||
| A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCN[NCT02315326] | Phase 1/Phase 2 | 109 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies[NCT02329847] | Phase 1/Phase 2 | 144 participants (Actual) | Interventional | 2015-03-11 | Completed | ||
| A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.[NCT02006485] | Phase 1 | 160 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| A Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL)[NCT01569750] | Phase 1 | 33 participants (Actual) | Interventional | 2012-06-14 | Completed | ||
| A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma[NCT01479842] | Phase 1 | 48 participants (Actual) | Interventional | 2011-12-07 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (>=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Months (Median) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 11.5 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 19.2 |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 10.2 |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 6.9 |
Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years and 11 months
| Intervention | Months (Median) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 24.8 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 20.8 |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 17.38 |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 14.55 |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 14.1 |
ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/L, platelets >100*10^9/L, Hgb >11 g/dL and absolute lymphocyte count <4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- >=50% drop in lymphocyte count from baseline or <=4.0*10^9/L with following: >=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, >=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils >1.5*10^9/L, Platelets>100000/mcL and Hgb>11 g/dL or >=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) | 63.3 |
ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) >= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ibrutinib and Nivolumab: Small Lymphocytic Lymphoma (SLL) | 50.0 |
| Ibrutinib and Nivolumab: Follicular Lymphoma (FL) | 32.5 |
| Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) | 37.8 |
| Ibrutinib and Nivolumab: Richter | 65.0 |
OS was defined as duration from the date of first dose of study drug to the date of the participant's death. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Months (Median) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 12.4 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | NA |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 19.0 |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 10.3 |
Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 14.3 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 42.9 |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 74.3 |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 25.7 |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 54.1 |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 60.0 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent. (NCT02329847)
Timeframe: Up to 6 years 10 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 100 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 100 |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 100 |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 100 |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 97.3 |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 95.0 |
PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months
| Intervention | Months (Median) |
|---|---|
| Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 2.0 |
| Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 9.1 |
| Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 21.6 |
| Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 7.6 |
| Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 3.2 |
| Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 5.0 |
11 reviews available for adenine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Topics: Adenine; Antineoplastic Agents; Atrial Fibrillation; B-Lymphocytes; Bridged Bicyclo Compounds, Heter | 2018 |
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Design; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Thera | 2018 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; L | 2018 |
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunoth | 2019 |
Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Bone Marrow; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperid | 2019 |
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Topics: Adenine; Animals; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non- | 2014 |
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chron | 2014 |
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine- | 2014 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt | 2015 |
[Acyclic nucleoside phosphonates as potential antineoplastic agents].
Topics: Adenine; Alanine; Animals; Antineoplastic Agents; Cell Line, Tumor; Guanine; Humans; Lymphoma, Non-H | 2008 |
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Drug De | 2012 |
8 trials available for adenine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, | 2022 |
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic | 2019 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dose-Response Relationship, Drug; Fema | 2019 |
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derive | 2014 |
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2015 |
Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adenine; Adult; Aged; Aminoquinolines; Antineoplastic Agents; Disease-Free Survival; Dose-Response R | 2015 |
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.
Topics: Adenine; Administration, Oral; Area Under Curve; Humans; Infusions, Intravenous; Leukemia, Hairy Cel | 2004 |
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Topics: Acetylation; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Femal | 1995 |
28 other studies available for adenine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Immunocompromised Host; Invasive Fungal Inf | 2019 |
Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Hepatitis B virus; Humans; Liver Failure; Lymphoma, Non-Hodgkin; M | 2020 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells.
Topics: Adenine; Central Nervous System; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Lympho | 2021 |
Prognostic value of [
Topics: Adenine; Fluorodeoxyglucose F18; Glycolysis; Humans; Lymphoma, Non-Hodgkin; Piperidines; Positron Em | 2021 |
Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; CD79 Antigens; Cell Proliferat | 2017 |
Imbruvica
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Le | 2017 |
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Topics: Adenine; Animals; Antineoplastic Agents; Benzodiazepines; Cell Death; Cell Line, Tumor; Cell Prolife | 2017 |
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2018 |
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Re | 2018 |
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medication Adh | 2019 |
Precision therapies take aim at non-Hodgkin's lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Disease Models, Animal; Dogs; Drug Approval; | 2018 |
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female; | 2014 |
A treatment for activated B-cell-like DLBCL?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherap | 2014 |
T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.
Topics: Adenine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; GATA3 Transcription Factor | 2017 |
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell De | 2017 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanin | 2010 |
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-D | 2012 |
PHYSIOLOGICAL DISPOSITION AND THERAPEUTIC CONSEQUENCES OF ADENINE ADMINISTERED VIA THE GASTROINTESTINAL TRACT IN NORMAL AND TUMOR-BEARING MICE.
Topics: Adenine; Adenine Nucleotides; Animals; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatoc | 1963 |
THE CHEMOTHERAPY OF CANCER WITH MASSIVE DOSES UNDER THE PROTECTION OF PERFUSION OF AUTOGENOUS HEMATOPOIETIC TISSUE.
Topics: Adenine; Bone Marrow Transplantation; Breast Neoplasms; DNA; Female; Folic Acid; Humans; Lung Neopla | 1964 |
TUMOR-HOST RELATIONSHIPS STUDIED IN VITRO: EXPERIMENTS WITH TISSUE SLICES.
Topics: Adenine; Carcinoma 256, Walker; DNA; In Vitro Techniques; Kidney; Liver; Lung; Lymphoma, Non-Hodgkin | 1964 |
THE ENZYMATIC SYNTHESIS OF RIBONUCLEIC ACID IN ANIMAL TISSUE. I. THE DEOXYRIBONUCLEIC ACID-DIRECTED SYNTHESIS OF RIBONUCLEIC ACID AS CATALYZED BY AN ENZYME OBTAINED FROM BOVINE LYMPHOSARCOMA TISSUE.
Topics: Adenine; Animals; Catalysis; Cattle; Cytosine; DNA; DNA Replication; DNA, Bacterial; Enzootic Bovine | 1965 |
Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma.
Topics: Adenine; Adult; Antiviral Agents; Carrier State; Drug Resistance; Female; Hepatitis B; Humans; Lamiv | 2004 |
[Adefovir in reactivation of chemotherapy-induced hepatitis B in an anti-Hbc-positive patient].
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Dacarbaz | 2007 |
Mechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells.
Topics: 2-Aminopurine; Adenine; Animals; Base Sequence; Cell Line; Cytidine Triphosphate; DNA; DNA Repair; D | 1982 |
Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days.
Topics: Adenine; Antigens, CD; Antigens, CD34; Blood Preservation; Breast Neoplasms; Cell Culture Techniques | 2001 |
Analysis of adenosine-mediated pyrimidine starvation using cultured wild-type and mutant mouse T-lymphoma cells.
Topics: Adenine; Adenine Phosphoribosyltransferase; Adenosine; Adenosine Deaminase Inhibitors; Adenosine Kin | 1978 |
Nucleic acids of bovine lymphosarcoma and normal thymus.
Topics: Adenine; Animals; Carbon Isotopes; Cattle; Cytosine; DNA, Neoplasm; Electrophoresis; Guanine; Lympho | 1968 |